We are pleased to announce the induction of David Bearss Ph.D. to our strategic advisory board as a key advisor for clinical trials.

Dr. David Bearss is the CEO of Halia Therapeutics, Inc. He is an experienced entrepreneur and drug developer with 20 plus years of experience in academic and industry settings.

We are confident that Dr. Bearss’ comprehensive understanding of the drug development life cycle and technical expertise in all aspects of patient care will add immeasurable value to our Customer’s Clinical Development Plans.

CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION

About CBCC Global Research

At CBCC Global Research, we are accelerating medical therapy development by providing high-quality, affordable and innovative solutions.

We provide strategic solutions for all phases of clinical trials through efficient delivery of services for the flawless execution of projects, on time – every time.

We are committed to achieving excellence in all research projects by ensuring scientific validity, data integrity, and compliance with the latest regulatory guidelines, thus striving to be a leading global clinical research organization (CRO).